4.5 Article

Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France

Journal

VACCINE
Volume 36, Issue 45, Pages 6591-6593

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2018.09.029

Keywords

RSV; Bronchiolitis; Vaccine; Acute respiratory infection; Cost effectiveness; Burden of disease; Cost analysis

Ask authors/readers for more resources

Objectives: We aimed to describe direct medical costs of annual RSV-associated hospitalisation in the first year of life. Methods: Retrospective cohort study in Lyon, France (2012-2016). A case was defined as a laboratory confirmed RSV-infection with hospitalisation in the first year of life. Hospital costs were estimated based on the French version of Diagnosis Related Groups. Results: Overall, 350 cases in 21,930 children were identified. Incidence of RSV-associated hospitalisation in the first year of life per 1000 births was 14.5 (95% CI 13.4-15.6). Related direct medical annual costs were 364,269 (sic), mostly attributed to children born during the RSV season (231,959 (sic)) and children born premature (108,673 (sic)). Conclusion: Medical costs for RSV-associated hospitalisation of newborns are higher for children born premature or born during the RSV season. Prioritised targeting of those groups may facilitate a costefficient strategy for the national prevention program. (C) 2018 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available